Tricuspid regurgitation occurs when the tricuspid valve in the heart does not close properly, allowing blood to leak into the right atrium. It significantly impacts mortality, risk of cardiovascular events and quality of life.
Currently 550,000 patients develop this disease in the US and Europe alone but less than 1% receive surgical treatment. This is because they are too high risk for surgery due to age and other co-morbidities demonstrating the significant clinical need for a minimally invasive solution. This means they live with a significantly reduced quality of life, as well as adding an enormous burden to healthcare systems as they require repeat hospitalisations.
Our proposed technology is safe, durable, cost effective and is technically straightforward to implant. The innovative elements of this proprietary solution are that it works in tandem with the native valve and uses existing interventional techniques for delivery. The resulting procedure is safe and easy to execute ensuring a high physician adoption rate for this solution which is a significant differentiator when compared to our competitors.